Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~* • The patient is a man or woman aged ≥65 yrs~  * The patient has Major Depressive Disorder according to Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR™).~ * The patient has an inadequate response to at least one adequate antidepressant treatment in the current Major Depressive Episode (MDE).~ * The patient has had the current MDE for ≥8 weeks~ * The patient is currently treated with a protocol specified ADT for at least 6 weeks~ * The patient is judged to benefit from adjunctive treatment with brexpiprazole according to the clinical opinion of the investigator.~ * Montgomery and Åsberg Depression Rating Scale (MADRS) total score \> 18 at screening and baseline~ * Clinical Global Impression - Severity (CGI-S) total score ≥3 at screening and baseline~Main Exclusion Criteria:~* • The patient has a clinically significant unstable illness~  * The patient has newly diagnosed or unstable diabetes~ * The patient has a Mini Mental State Exam (MMSE) score \<24~ * The patient has received Transcranial Magnetic Stimulation (TMS) and/or electroconvulsive therapy (ECT) less than 6 months prior to the Screening.~ * The patient, in the opinion of the investigator or based on Columbia-Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation and behaviour rating, is at significant risk of suicide~Other protocol defined inclusion and exclusion criteria may apply

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adjunct brexpiprazole (Type: EXPERIMENTAL): All patients continue their current antidepressant treatment (ADT) and receive brexpiprazole in addition

Based on this trial design, predict the completion outcome and termination type (if applicable).